Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%Investors Business Daily • 12/26/23
Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'24/7 Wall Street • 12/26/23
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioGlobeNewsWire • 12/26/23
Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billionMarket Watch • 12/26/23
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.PRNewsWire • 12/22/23
Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B dealProactive Investors • 12/22/23
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales OutlookInvestopedia • 12/22/23
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna DealInvestopedia • 12/22/23
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 BillionBusiness Wire • 12/22/23